Vivos Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Vivos Therapeutics, Inc. (VVOS) reported Net Income (Loss) Available to Common Stockholders, Basic of -$5.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-14
- Vivos Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$5.48M.
- Vivos Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$7.68M.
- Vivos Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$6.95M.
- Vivos Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$5.40M.
- Vivos Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$21.23M.
- Vivos Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$11.14M.
- Vivos Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$13.58M.
- Vivos Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$23.84M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.48M 10-Q · filed 2026-08-14 | -$13.16M 10-Q · filed 2026-08-14 | -$20.12M derived: sum of 3 quarters · filed 2026-08-14 | -$25.52M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | -$7.68M 10-Q · filed 2026-05-20 | -$14.64M derived: sum of 2 quarters · filed 2026-05-20 | -$20.04M derived: sum of 3 quarters · filed 2026-05-20 | -$25.05M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | -$6.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$12.35M derived: sum of 2 quarters · filed 2026-04-15 | -$17.37M derived: sum of 3 quarters · filed 2026-08-14 | -$21.23M 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | -$5.40M 10-Q · filed 2025-11-19 | -$10.41M derived: sum of 2 quarters · filed 2026-08-14 | -$14.28M 10-Q · filed 2025-11-19 | -$17.10M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | -$5.01M 10-Q · filed 2026-08-14 | -$8.88M 10-Q · filed 2026-08-14 | -$11.70M derived: sum of 3 quarters · filed 2026-08-14 | -$14.32M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | -$3.86M 10-Q · filed 2026-05-20 | -$6.69M derived: sum of 2 quarters · filed 2026-05-20 | -$9.31M derived: sum of 3 quarters · filed 2026-05-20 | -$11.24M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-12-31 | -$2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$5.44M derived: sum of 2 quarters · filed 2026-04-15 | -$7.37M derived: sum of 3 quarters · filed 2026-04-15 | -$11.14M 10-K · filed 2026-04-15 | ||||
| 2024-09-30 | -$2.62M 10-Q · filed 2025-11-19 | -$4.55M derived: sum of 2 quarters · filed 2025-11-19 | -$8.31M 10-Q · filed 2025-11-19 | -$12.57M derived: sum of 4 quarters · filed 2025-11-19 | ||||
| 2024-06-30 | -$1.93M 10-Q · filed 2025-08-19 | -$5.69M 10-Q · filed 2025-08-19 | -$9.95M derived: sum of 3 quarters · filed 2025-08-19 | -$12.04M derived: sum of 4 quarters · filed 2025-08-19 | ||||
| 2024-03-31 | -$3.76M 10-Q · filed 2025-05-15 | -$8.02M derived: sum of 2 quarters · filed 2025-05-15 | -$10.12M derived: sum of 3 quarters · filed 2025-05-15 | -$15.64M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$6.35M derived: sum of 2 quarters · filed 2025-03-31 | -$11.88M derived: sum of 3 quarters · filed 2025-03-31 | -$13.58M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$2.09M 10-Q · filed 2024-11-14 | -$7.62M derived: sum of 2 quarters · filed 2024-11-14 | -$9.32M 10-Q · filed 2024-11-14 | -$15.41M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | -$5.53M 10-Q · filed 2024-08-14 | -$7.23M 10-Q · filed 2024-08-14 | -$13.32M derived: sum of 3 quarters · filed 2024-08-14 | -$18.75M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | -$1.70M 10-Q · filed 2024-05-14 | -$7.79M derived: sum of 2 quarters · filed 2024-07-30 | -$13.23M derived: sum of 3 quarters · filed 2024-07-30 | -$20.22M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-12-31 | -$6.09M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-07-30 | -$11.52M derived: sum of 2 quarters · filed 2024-07-30 | -$18.52M derived: sum of 3 quarters · filed 2024-07-30 | -$23.84M 10-K/A · filed 2024-07-30 | ||||
| 2022-09-30 | -$5.43M 10-Q · filed 2023-11-14 | -$12.43M derived: sum of 2 quarters · filed 2023-11-14 | -$17.76M 10-Q · filed 2023-11-14 | -$25.15M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$6.99M 10-Q · filed 2023-08-16 | -$12.32M 10-Q · filed 2023-08-16 | -$19.72M derived: sum of 3 quarters · filed 2023-08-16 | -$25.17M derived: sum of 4 quarters · filed 2023-08-16 | ||||
| 2022-03-31 | -$5.33M 10-Q · filed 2023-06-08 | -$5.51M 10-Q · filed 2022-05-16 | -$12.72M derived: sum of 2 quarters · filed 2023-06-08 | -$18.18M derived: sum of 3 quarters · filed 2023-06-08 | -$22.22M derived: sum of 4 quarters · filed 2023-06-08 | |||
| 2021-12-31 | -$7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$12.85M derived: sum of 2 quarters · filed 2023-03-30 | -$16.89M derived: sum of 3 quarters · filed 2023-03-30 | -$20.29M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | -$5.45M 10-Q · filed 2022-12-20 | -$5.45M 10-Q · filed 2021-11-15 | -$9.50M derived: sum of 2 quarters · filed 2022-12-20 | -$12.89M 10-Q · filed 2022-12-20 | -$12.90M 10-Q · filed 2021-11-15 | -$24.33M derived: sum of 4 quarters · filed 2022-12-20 | ||
| 2021-06-30 | -$4.04M 10-Q · filed 2022-12-20 | -$4.04M 10-Q · filed 2021-08-12 | -$7.44M 10-Q · filed 2022-12-20 | -$7.44M 10-Q · filed 2021-08-12 | -$18.87M derived: sum of 3 quarters · filed 2022-12-20 | -$20.94M derived: sum of 4 quarters · filed 2022-12-20 | ||
| 2021-03-31 | -$3.40M 10-Q/A · filed 2022-11-25 | -$3.40M 10-Q · filed 2021-05-17 | -$14.83M derived: sum of 2 quarters · filed 2022-11-25 | -$16.89M derived: sum of 3 quarters · filed 2022-11-25 | -$18.56M derived: sum of 4 quarters · filed 2022-11-25 | |||
| 2020-12-31 | -$11.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$13.49M derived: sum of 2 quarters · filed 2022-03-31 | -$15.16M derived: sum of 3 quarters · filed 2022-03-31 | -$17.99M 10-K · filed 2022-03-31 | -$17.99M 10-K · filed 2021-03-25 | |||
| 2020-09-30 | -$2.06M 10-Q · filed 2021-11-15 | -$3.73M derived: sum of 2 quarters · filed 2021-11-15 | -$6.56M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | -$1.66M 10-Q · filed 2021-08-12 | -$4.49M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$2.83M 10-Q · filed 2021-05-17 | |||||||
| 2019-12-31 | -$11.75M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |